fda glp-1 compounding warning october 2025 Beyond the Headlines: Letters to Compounders FDA warns against compounded GLP-1

Yes, many patients find compounded semaglutide from licensed 503A pharmacies equally effective for weight loss while experiencing fewer headaches, possibly due to differences in formulation, stabilizers, or the ability to customize dosing schedules

RSI and MACD RSI (68.36) has moved close to overbought territory, indicating strong momentum and continued institutional buying interest, though the stock may experience periodic consolidation after its recent rally

If you are seeking significant weight loss backed by clinical studies, FDA-approved medications or supervised medical programs may be more appropriate

Daniela Hurtado Andrade, M.D., PhD, an endocrinologist at Mayo Clinic